By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Tax Strategy & Growth Planning · Los Angeles, CA | Published July 2026 | Cannabis Advisory
A single announcement is reshaping cannabis tax planning in 2026, and every qualifying medical cannabis operator needs to understand it correctly. On April 23, 2026, the US Department of the Treasury and the IRS issued a press release stating that forthcoming guidance will include a transition rule. Under that rule, the April 22 rescheduling of medical cannabis to Schedule III will apply to a business's full taxable year that includes the effective date. For calendar-year operators, that means the entire 2026 tax year, not just the period from April 22 forward. Many practitioners expected a less favorable result. One important precision point: as of this article's publication date, the IRS has not issued formal guidance. Treasury announced its intent. The actual guidance that governs how operators file is still forthcoming.
QUICK ANSWER
Treasury has announced that forthcoming IRS guidance is expected to provide that 280E relief applies to the full 2026 taxable year for qualifying medical cannabis operators, not just from April 22 forward. Formal guidance has not yet been published. The priority actions for medical operators are: recalculate Q3 and Q4 estimated tax payments, file protective refund claims for open prior years, and implement newly available deductions before December 31. Changing your fiscal year to capture earlier relief is high-risk and unnecessary for calendar-year operators. Adult-use cannabis remains Schedule I and 280E fully applies, unchanged.
Cannabis Tax Planning After Rescheduling: At a Glance
- What it covers: Strategic tax planning for qualifying state-licensed medical cannabis operators following the April 22, 2026 DOJ rescheduling order and Treasury's April 23 announcement on the expected transition rule.
- Who it applies to: State-licensed medical cannabis operators whose activities qualify for Schedule III treatment. Adult-use operators: no change from prior law, 280E fully applies.
- Key development: Treasury has announced that forthcoming guidance is expected to apply 280E relief to the full taxable year that includes April 22, 2026. For calendar-year operators, that is January 1 through December 31, 2026.
- Important caveat: Formal IRS guidance has not yet been published. Do not file amended returns, reclassify accounting entries, or change tax positions until guidance is officially issued.
- Priority actions now: Recalculate Q3 estimated tax payments, prepare protective refund claims for open prior years, and identify the new deductions available post-280E for implementation before December 31.
- Fiscal year change: High-risk and unnecessary for calendar-year operators. IRS approval requires a valid business purpose beyond tax savings, and the transition rule already delivers the full-year benefit without a year change.
Ready to rebuild your 2026 tax projection? Book a CFO Discovery Call to get started →
What the Treasury Announcement Means for 2026 Tax Year Planning
On April 23, 2026, Treasury and the IRS issued a press release stating they will issue guidance addressing the federal tax consequences of the DOJ's rescheduling order. That guidance will include a transition rule: for Section 280E purposes, rescheduling will generally apply for the business's full taxable year that includes the effective date of the Final Order. For calendar-year taxpayers, 280E relief covers the full 2026 tax year, not just from April 22 forward.
What the Full-Year Rule Means in Dollars
The practical significance is substantial. Take a medical cannabis dispensary that ran under 280E for the first four months of 2026, blocking deductions on rent, payroll, marketing, and other SG&A expenses during that period. Under the transition rule, the business treats those expenses as deductible for the full year. For a dispensary with $500,000 in annual SG&A, the January-through-April portion represents roughly $165,000 in expenses the operator now expects to deduct. That is the retroactive benefit within the current year, before any forward-looking planning.
What Has Not Yet Happened
Treasury announced its intent. The IRS has not published formal guidance. Operators should not file amended returns claiming 280E relief, reclassify operating expenses as deductible in their accounting systems, or change their tax positions based on the announcement alone. The announced transition rule will almost certainly become formal guidance, and it is the right framework to model against now. Acting before the guidance arrives creates unnecessary exposure. GreenGrowth recommends that medical operators rebuild their 2026 tax projections using the announced framework, keep conservative documentation, and wait for formal guidance before filing any changes.
The Prior-Year Question Is Separate
The transition rule addresses 2026 and forward. Whether medical operators can recover prior-year 280E payments for FY2022, FY2023, and FY2024 is a separate question the Treasury announcement did not fully resolve. The DOJ rescheduling order encouraged Treasury to consider retrospective relief for prior years in which operators held state medical licenses. That encouragement does not constitute guidance. Most medical operators should file protective refund claims for open prior years now. This step preserves the statute of limitations without committing to a litigation posture, while Treasury works through the retroactivity question.
💬 The Conversation Worth Having
Every medical cannabis operator we talk to right now wants to know the same thing: can we stop making the same estimated tax payments we were making under 280E? The answer is yes, with an important qualifier. Your Q3 and Q4 payments should be recalculated using a projection that reflects expected 280E relief. The prior-year safe harbor calculation is almost certainly overstating your required payment if you used a 280E-heavy tax rate as the base. Overpaying estimated taxes is not a safety strategy. It is cash that sits with the IRS until you file and get it back -- while your operation is using a line of credit to fund operations it could have funded with its own money.
Your Q3 estimated tax payment may be overstated. Let's model the right number before September 15.
Book a Review →The Fiscal Year Change Question: Why It Is High-Risk
When rescheduling was first announced, several cannabis advisors suggested that operators should consider changing their fiscal year to begin after April 22, so that their first post-rescheduling year would start sooner than January 1, 2027. Treasury's announced transition rule makes this strategy largely unnecessary for calendar-year taxpayers, who already expect to receive the full 2026 benefit. For fiscal-year taxpayers whose year-end is not December 31, the analysis is more nuanced, but the risks remain significant.
IRS Approval Requirements
Changing a tax year requires IRS approval. The rules vary by entity type. S-Corps are generally limited to permitted year-ends under Revenue Procedure 2006-46. Partnerships must use their required taxable year unless they can show the IRS a valid business purpose. C-Corps have more flexibility but still need approval for voluntary changes. The IRS does not approve year changes simply to reduce tax liability. Capturing 280E relief earlier does not qualify as a valid business purpose on its own.
Calendar-year operators should not pursue a fiscal year change. The transition rule already delivers the full-year benefit for 2026. Fiscal-year operators with a year-end other than December 31 should consult their cannabis tax advisor, understand the approval requirements and challenge risk, and weigh the expected benefit carefully against the cost and complexity of the process. For more on how we approach these decisions, see our cannabis advisory services.
Priority Tax Planning Actions Before Year-End 2026
Qualifying medical cannabis operators have a defined window to act before December 31. The planning decisions made in Q3 and Q4 2026 will determine how much of the available benefit actually lands on the 2026 return.
Recalculate Q3 and Q4 Estimated Tax Payments
Prior-year safe harbor calculations used a 280E-heavy effective tax rate as the base. For qualifying medical operators, that calculation now overstates the required payment. The September 15 Q3 deadline is approaching. Overpaying estimated taxes is not a conservative strategy. It locks money with the IRS until the return goes in and the refund processes. Rebuild your 2026 tax projection using the expected post-280E rate, then recalculate Q3 and Q4 accordingly. Our tax planning and estimated payment services team handles this recalculation for cannabis clients now.
File Protective Refund Claims for Open Prior Years
The statute of limitations for FY2022 and FY2023 refund claims is running. Calendar-year operators who filed their 2022 return on April 15, 2023 without an extension may have a window closing now or already closed. Filing a protective refund claim preserves the clock without committing to a litigating posture. It is an inexpensive step that keeps options open while Treasury works through the retroactivity question. Do not wait for guidance to start this process.
Implement New Deductions Available Post-280E
Beyond restoring basic SG&A deductibility, qualifying medical operators now access a longer list of deductions and credits that 280E previously blocked. The R&D credit under IRC Section 41 cuts income tax liability by 5 to 10% of qualifying R&D expenses, including payroll for product development and quality testing. Section 179 and bonus depreciation on equipment and leasehold improvements now generate real federal tax benefit. Retirement plan contributions for owners and employees -- SEP-IRA, Solo 401(k), and defined benefit plans -- reduce taxable income in the year you fund them.
Why Q3 Is the Right Time to Start
The planning window for 2026 closes December 31. Starting in Q3 gives meaningful time to act on each of these strategies. An operator who waits until November faces fewer options and tighter execution windows. Take one example: a medical cannabis dispensary with $100,000 in qualifying R&D expenses, $50,000 in bonus-depreciation-eligible equipment, and $60,000 in retirement contributions can cut taxable income by $210,000 before adding any SG&A deductions. That is a real number, and it requires decisions made now, not in Q4.
▶ New Deductions Available for Qualifying Medical Cannabis Operators in 2026
| Deduction / Credit | Provision | Est. Tax Benefit |
|---|---|---|
| All ordinary SG&A expenses | IRC Section 162 | Entire SG&A base deductible |
| R&D credit on qualifying expenses | IRC Section 41 | 5-10% of qualifying R&D payroll and supplies |
| Equipment and leasehold improvements | Section 179 / Bonus depreciation | Full first-year deduction on qualifying assets |
| Owner and employee retirement contributions | SEP-IRA, Solo 401(k), defined benefit | Contributions reduce taxable income in year funded |
Applies to qualifying medical cannabis operators under the April 22, 2026 rescheduling order. Adult-use operators: 280E still applies, these deductions remain unavailable.
Does Every Medical Cannabis Operator Qualify for 280E Relief?
Not automatically. The April 22 DOJ order covers state-licensed medical cannabis operators, but qualifying depends on whether the operator's activities meet the definition in the order. Operators with exclusively medical licenses in pure medical states have the clearest path. Dual-license operators in adult-use states must allocate expenses between their medical and adult-use activities. Only the medical portion qualifies for 280E relief.
The Dual-License Allocation Challenge
For operators holding both a medical and adult-use license, the split is real and it matters. The medical side no longer faces federal 280E. The adult-use side does. Treasury plans to address how operators apportion expenses between the two activities in forthcoming guidance. Until that guidance arrives, dual-license operators should implement documented expense segregation between medical and adult-use functions. The methodology must hold up under examination. A combined operation that lacks documented separation loses the benefit on the medical side and creates audit exposure across the broader business. For cannabis tax compliance support on dual-license operations, our team works through this allocation process as part of the post-rescheduling planning engagement.
KEY TAKEAWAYS
- ›Treasury has announced that forthcoming IRS guidance is expected to apply 280E relief to the full 2026 taxable year for qualifying medical cannabis operators. Formal guidance has not yet been published. Do not file amended returns or change accounting until it is.
- ›For calendar-year medical operators, the expected retroactive benefit within 2026 is significant. A dispensary with $500,000 in annual SG&A has approximately $165,000 in expenses from January through late April that were expected to be disallowed and are now expected to be deductible.
- ›The fiscal year change strategy is high-risk and unnecessary for calendar-year operators. The IRS requires a valid business purpose beyond tax savings, and the transition rule already delivers the expected full-year benefit.
- ›Q3 and Q4 estimated tax payments should be recalculated. Prior-year safe harbor calculations built on 280E-heavy tax rates overstate the required payment for qualifying operators. The September 15 deadline is the next action date.
- ›Protective refund claims for FY2022 and FY2023 should be filed now to preserve statute-of-limitations optionality while formal Treasury guidance on retroactivity is awaited.
- ›Adult-use cannabis operators: 280E fully applies. No change from prior law. None of the 280E relief discussed in this article applies to adult-use operations.
Frequently Asked Questions
Treasury has announced that forthcoming IRS guidance is expected to include a transition rule providing that 280E relief applies to the full taxable year that includes the effective date of the DOJ Final Order (April 22, 2026). For calendar-year taxpayers, this means the full 2026 tax year. Formal IRS guidance confirming this rule has not yet been published as of this article's date.
This is the most favorable interpretation available, and it is the framework Treasury has publicly signaled. Medical operators should plan against this framework while waiting for formal guidance before filing changes. The prior-year question -- whether retroactive relief for FY2022, FY2023, and FY2024 is available -- is separate and has not been confirmed by Treasury guidance.
No, not for calendar-year taxpayers. Treasury's announced transition rule already provides the full 2026 tax year benefit without any year change. For fiscal-year taxpayers whose year-end is not December 31, the analysis is more complex, but the risks remain significant: IRS approval requires a valid business purpose beyond tax savings, the rules for S-Corps and partnerships are strict, and the risk of IRS challenge is real.
Any operator considering a fiscal year change should discuss it with their cannabis tax advisor and approach the decision with a clear understanding of the approval requirements, the risk profile, and the specific benefit their situation produces. In most cases, the expected benefit does not justify the complexity and risk of a voluntary year change.
Qualifying medical cannabis operators should recalculate their Q3 and Q4 2026 estimated federal tax payments to reflect the expected 280E relief. Prior-year safe harbor calculations overstate the required payment for operators who are now expected to be able to deduct SG&A for the full 2026 tax year. The September 15 Q3 deadline is the next action date.
Overpaying estimated taxes is not a conservative strategy. It is a cash flow decision that locks operating capital with the IRS until the return is filed. A well-calibrated estimated payment based on the expected post-280E tax rate is the correct approach. Work with your cannabis tax advisor to recalculate before September 15. Adult-use operators: no change, continue paying under current 280E rules.
Current Treasury guidance does not authorize retroactive 280E relief for prior tax years. The DOJ rescheduling order encouraged Treasury to consider retrospective relief for prior taxable years in which operators held state medical licenses, but that encouragement does not constitute guidance authorizing amended returns.
The recommended action for most medical operators with significant prior-year 280E payments is to file protective refund claims for open years -- FY2022 and FY2023 for most calendar-year operators -- to preserve the statute-of-limitations clock while formal guidance is awaited. Protective claims are inexpensive and preserve the option without committing to a litigation posture. Do not file amended returns claiming prior-year relief until formal Treasury guidance on retroactivity is published.
Qualifying medical cannabis operators now have access to the full range of ordinary business expense deductions under IRC Section 162: SG&A expenses including rent, payroll, marketing, utilities, and professional fees, all of which were previously disallowed at the retail stage under 280E. Beyond SG&A, operators now have access to the R&D credit under IRC Section 41, Section 179 and bonus depreciation on equipment and leasehold improvements, and retirement plan contributions for owners and employees.
A medical cannabis dispensary with $100,000 in qualifying R&D expenses, $50,000 in equipment eligible for bonus depreciation, and $60,000 in retirement contributions can reduce taxable income by $210,000 in the first year these strategies are available -- before any SG&A deductions. The planning window for 2026 implementation closes December 31.
We start by confirming whether the operator's activities qualify for Schedule III treatment under the April 22 order, which is not automatic for all medical license types or dual-license structures. We then rebuild the 2026 tax projection from scratch using the expected post-280E rate, recalculate Q3 and Q4 estimated payment obligations, and identify every available deduction and credit that should be implemented before December 31.
For dual-license operators, we build a documented expense allocation methodology between medical and adult-use activities that can withstand IRS scrutiny. For operators with significant prior-year 280E payments, we evaluate protective refund claim timing and coordinate on the broader retroactivity question as Treasury guidance develops. To start, book a CFO Discovery Call with our cannabis advisory team.
The Planning Window for 2026 Closes December 31
GreenGrowth CPAs works with qualifying medical cannabis operators to rebuild 2026 tax projections, recalculate estimated payments, file protective prior-year claims, and implement the deductions and credits available for the first time post-280E. Operators who act before Q4 will have materially better outcomes than those who wait until February.
KEY NUMBERS
280E Relief Is Here for Medical Operators. The Work Is in Capturing It.
Book a 2026 Tax Planning Review. We will rebuild your tax projection, recalculate your estimated payments, and identify every deduction available before December 31.
Book Your Free CFO Discovery Call →GreenGrowth CPAs · Cannabis Advisory Team
